Contributing Member of the Healthcare Councils
Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.
GLG News by this Author
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
-
GSK's cervical cancer vaccine Cervarix gains approval in Japan
October 19, 2009
GSK's cervical cancer vaccine Cervarix gains approval in Japan | www.pharmabiz.com
GlaxoSmithKline (GSK) gained approval for Cervarix in Japan, which becomes the first cervical cancer vaccine to be approved by the Japanese Ministry of Health, Labour and Welfare (MHLW). This approval marks a significant milestone for GSK, as Cervarix will be the first to be launched by the company's Japanese business.
-
Researchers herald 'breakthrough' skin cancer therapy
September 27, 2009
Researchers herald 'breakthrough' skin cancer therapy | www.fiercebiotech.com
Plexxikon's early stage experimental melanoma drug PLX4032 looks like a "major breakthrough," says one leading researcher after reviewing new data from a small trial.
-
Sanofi Pasteur Commends Results of First HIV Vaccine
September 25, 2009
Sanofi Pasteur Commends Results of First HIV Vaccine Study to Show Some Effectiveness in Preventing HIV | www.pipelinereview.com
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), commended the results of the collaborative HIV vaccine trial that has been conducted in Thailand over the past six years. The Phase III clinical trial involving more than 16,000 adult volunteers in Thailand has demonstrated that an investigational HIV vaccine regimen was safe and modestly effective in preventing HIV infection.
-
Roche's Herceptin provides impressive survival benefit
September 25, 2009
Roche's Herceptin provides impressive survival benefit in HER2-positive advanced gastric cancer | www.pharmabiz.com
A detailed analysis of the phase-III ToGA study revealed an unprecedented survival benefit for patients whose tumours exhibited a particularly high level of HER2 when Roche's Herceptin (trastuzumab) was added to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin). Based on the significant findings of the ToGA study.
-
New Innovative Delivery System
September 15, 2009
Wyeth Launches New Innovative Delivery System For Enbrel(R) (etanercept) | www.medicalnewstoday.com
Enbrel (etanercept), Wyeth's biological treatment for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis, is now available as a new easy-to-use pre-filled auto-injector device, known as the Enbrel MYCLIC pen.
-
Positive and Highly Significant Phase III Results
September 13, 2009
Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA | www.pipelinereview.com
Nitec Pharma, a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced positive results from the second pivotal phase III trial for its lead product, Lodotra.
-
Bayer and Algeta Enter Global Agreement
September 12, 2009
Bayer and Algeta Enter Global Agreement for Development and Commercialization of Treatment for Bone Metastases in Cancer Patients | www.pipelinereview.com
Bayer has entered into a global agreement with Algeta for the development and commercialization of Alpharadin, a novel alpha-emitting radiopharmaceutical, based on radium.
-
Four studies published in The Lancet show roflumilast
September 12, 2009
Four studies published in The Lancet show roflumilast (Daxas®), a new oral approach to COPD, improves lung function and reduces exacerbations | www.nycomed.com
Nycomed and Forest Laboratories today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.
-
GSK plans to introduce Relenza in the Indian market
September 12, 2009
GSK plans to introduce Relenza in the Indian market | economictimes.indiatimes.com
News announcement about GSK's negotiations with the Indian government for introducing its patented drug Relenza, which is used for the treatment of Influenza A H1N1.
-
PHOSPHAGENICS TO COMMENCE PHASE 2/3 TOPICAL DICLOFENAC TRIAL
September 12, 2009
PHOSPHAGENICS TO COMMENCE PHASE 2/3 TOPICAL DICLOFENAC TRIAL | www.pipelinereview.com
Progression to the next step of clinical trials for topical NSAID - Diclofenac.
-
September 11, 2009
Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients | www.pipelinereview.com
Head to head trial of Ticagrelor vs Clopidogrel in reduction of cardiovascular accidents in patients with ACS.
-
Importing health care: trials and tribulations
May 26, 2009
India`s pharma exports to US tumble 37%: report | www.indiainfoline.com
The specific content of the article is less important than its implications, which may be interpreted as significant by some. As we know, the global economic slowing/recession has shown its effects, to some degree, in every market we know.
Page : 11 to 12 of 12
- Subscribe to Updates
-
This author consults with leading institutions through GLG
Most Popular Healthcare News
-
What is potential future for Sequenom in prenatal testing.
November 9, 2009
-
November 7, 2009
-
Express Scripts feeling Growing Pains
October 29, 2009
-
CDC Outlines H1N1 Test Guidelines
October 8, 2009
-
Why Health Care Costs Keep Rising—And What to Do About It
September 13, 2009